Danaher Corporation key statistics and ratios
In fiscal 2025, Danaher Corporation had return on equity of 7.1%, an operating margin of 19.1%, debt equal to 35.1% of equity and a current ratio of 1.87. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 48.2% | 51.0% | 50.8% | 51.6% | 51.1% | 53.2% | 53.8% | 55.3% | 46.8% | 47.8% | 55.7% | 56.0% | 61.4% | 60.8% | 58.7% | 59.5% | 59.1% | 58.6% |
| Operating margin | 13.7% | 16.3% | 16.3% | 17.3% | 17.1% | 15.9% | 15.0% | 16.2% | 14.0% | 15.4% | 18.3% | 19.0% | 25.7% | 28.3% | 21.8% | 20.4% | 19.1% | 20.4% |
| Net margin | 11.0% | 14.3% | 13.5% | 13.1% | 14.7% | 20.2% | 23.3% | 15.1% | 13.6% | 13.3% | 16.8% | 16.4% | 25.9% | 27.1% | 19.9% | 16.3% | 14.7% | 16.9% |
| Free-cash-flow margin | 15.5% | 15.1% | 14.2% | 16.2% | 16.7% | 25.6% | 22.8% | 17.4% | 15.9% | 17.3% | 18.5% | 24.3% | 28.7% | 27.8% | 24.2% | 22.2% | 21.4% | 22.4% |
| Return on equity | 9.9% | 14.2% | 14.2% | 13.3% | 13.0% | 11.4% | 14.3% | 10.9% | 10.1% | 9.7% | 10.3% | 10.4% | 15.1% | 15.1% | 9.2% | 7.6% | 7.1% | 8.2% |
| Return on assets | 5.9% | 8.6% | 8.3% | 7.6% | 8.0% | 7.3% | 7.9% | 5.5% | 5.4% | 5.6% | 5.5% | 5.3% | 8.1% | 8.6% | 5.6% | 4.8% | 4.5% | 4.9% |
| Asset turnover | 0.54 | 0.60 | 0.62 | 0.58 | 0.54 | 0.36 | 0.34 | 0.36 | 0.40 | 0.42 | 0.33 | 0.32 | 0.31 | 0.32 | 0.28 | 0.29 | 0.31 | 0.29 |
| Current ratio | 1.89 | 1.83 | 1.50 | 1.80 | 2.01 | 1.75 | 1.27 | 0.97 | 1.43 | 1.47 | 5.19 | 1.86 | 1.43 | 1.89 | 1.68 | 1.40 | 1.87 | 1.63 |
| Debt to equity | 26.8% | 21.9% | 37.2% | 34.5% | 17.6% | 18.1% | 54.3% | 53.3% | 39.9% | 34.5% | 71.8% | 53.3% | 49.1% | 39.3% | 34.4% | 32.3% | 35.1% | 49.4% |
| Interest cover (operating income ÷ interest) | 12.1x | 17.5x | 18.5x | 20.1x | 22.1x | 21.6x | 15.5x | 14.8x | 18.4x | 22.3x | 30.3x | 15.4x | 27.6x | 36.9x | 18.2x | 17.5x | 17.7x | 14.5x |
| Effective tax rate | 18.0% | 22.9% | 20.9% | 23.6% | 24.2% | 21.5% | 14.4% | 17.5% | 14.6% | 18.8% | 26.4% | 18.9% | 16.3% | 11.4% | 16.3% | 16.1% | 15.0% | 11.0% |
| R&D as % of revenue | 5.7% | 6.2% | 6.3% | 6.2% | 6.0% | 6.0% | 6.0% | 5.8% | 5.2% | 5.3% | 6.3% | 6.0% | 6.0% | 5.7% | 6.3% | 6.6% | 6.5% | 6.5% |
| SG&A as % of revenue | 29.6% | 28.7% | 28.6% | 28.4% | 28.0% | 31.4% | 32.9% | 33.3% | 27.5% | 27.1% | 31.2% | 30.9% | 27.5% | 26.7% | 30.7% | 32.5% | 33.5% | 31.7% |
| Capital spending as % of revenue | 1.7% | 1.5% | 2.1% | 2.5% | 2.9% | 3.6% | 3.6% | 3.5% | 3.1% | 2.9% | 3.6% | 3.5% | 5.0% | 4.2% | 5.8% | 5.8% | 4.7% | 4.4% |
| Free cash flow ÷ net income | 141.1% | 105.6% | 105.5% | 123.6% | 113.1% | 126.7% | 98.0% | 114.8% | 116.7% | 129.7% | 110.2% | 148.6% | 110.6% | 102.7% | 121.3% | 135.8% | 145.5% | 132.2% |
| Dividends ÷ net income | 3.6% | 2.9% | 2.8% | 3.6% | 1.9% | 8.8% | 10.5% | 15.7% | 15.2% | 16.3% | 17.5% | 16.9% | 11.5% | 11.3% | 17.2% | 19.7% | 24.3% | 23.5% |
| Dividends and buybacks ÷ free cash flow | 2.6% | 2.8% | 2.7% | 24.9% | 1.7% | 6.9% | 10.8% | 13.6% | 13.0% | 12.6% | 15.9% | 11.4% | 10.4% | 11.1% | 14.2% | 127.4% | 75.4% | 33.4% |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 59.5% | 61.2% | 59.3% | 58.2% | 58.0% | 60.3% | 57.6% | 58.5% |
| Operating margin | 21.8% | 22.2% | 12.8% | 19.1% | 22.0% | 22.6% | 18.0% | 19.0% |
| Net margin | 16.6% | 16.6% | 9.3% | 15.0% | 17.5% | 17.3% | 13.9% | 18.8% |
| Free-cash-flow margin | 23.0% | 18.4% | 18.4% | 22.6% | 25.5% | 18.2% | 20.2% | 24.9% |
| Current ratio | 1.40 | 1.43 | 1.62 | 1.52 | 1.87 | 1.87 | 1.65 | 1.63 |
| Debt to equity | 32.3% | 32.4% | 33.2% | 33.0% | 35.1% | 34.9% | 50.5% | 49.4% |
| R&D as % of revenue | 6.8% | 6.6% | 6.8% | 6.2% | 6.4% | 6.5% | 6.6% | 6.6% |
| SG&A as % of revenue | 30.9% | 32.4% | 39.8% | 32.9% | 29.6% | 31.3% | 33.1% | 32.9% |
Financial health
- Short-term assets cover short-term liabilities $14.8bn of assets due within a year against $9.1bn of liabilities due within a year.
- Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
- More cash than debt $5.7bn of cash against $26.5bn of debt.
- Debt below 40% of shareholders' equity Debt is 49% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 47% to 49% over five years.
- A year's operating cash flow covers at least 20% of debt $6.9bn of operating cash flow against $26.5bn of debt.
- Operating profit covers interest at least five times over Operating income of $5.2bn against $360m of interest.
Moat
Strong moat
How hard Danaher's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 6 / 20
Net income has been a median 5.1% of total assets over 10 years.
- Pricing power 18 / 20
Gross margin has been a median 58.7%, moving by 3.5 percentage points (standard deviation) across 10 years.
- Durability 16 / 20
Operating margin has been a median 19.6%; its worst year was 15.6%.
- Cash conversion 20 / 20
Free cash flow was positive in 10 of 10 years, at a median 21.4% of revenue.
- Discipline 18 / 20
The diluted share count fell 2.9% over five years; stock-based pay has been a median 1.0% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (78 before it).
Compare with peers
- IQVIA statistics
- Thermo Fisher Scientific statistics
- Icon PLC statistics
- Agilent Technologies statistics
- Avantor, Inc. statistics
Head to head: DHR vs IQVDHR vs TMODHR vs ICLR
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies